The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
The Heat Shock Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-binding Domain in the Carboxyl Terminus of the Chaperone
Open accessAbstract
Heat shock protein 90 (Hsp90), one of the most abundant chaperones in eukaryotes, participates in folding and stabilization of signal-transducing molecules including steroid hormone receptors and protein kinases. The amino terminus of Hsp90 contains a non-conventional nucleotide-binding site, related to the ATP-binding motif of bacterial DNA gyrase. The anti-tumor agents geldanamycin and radicicol bind specifically at this site and induce destabilization of Hsp90-dependent client proteins. We recently demonstrated that the gyrase inhibitor novobiocin also interacts with Hsp90, altering the affinity of the chaperone for geldanamycin and radicicol and causing in vitro and in vivo depletion of key regulatory Hsp90-dependent kinases including v-Src, Raf-1, and p185(ErbB2). In the present study we used deletion/mutation analysis to identify the site of interaction of novobiocin with Hsp90, and we demonstrate that the novobiocin-binding site resides in the carboxyl terminus of the chaperone. Surprisingly, this motif also recognizes ATP, and ATP and novobiocin efficiently compete with each other for binding to this region of Hsp90. Novobiocin interferes with association of the co-chaperones Hsc70 and p23 with Hsp90. These results identify a second site on Hsp90 where the binding of small molecule inhibitors can significantly impact the function of this chaperone, and they support the hypothesis that both amino- and carboxyl-terminal domains of Hsp90 interact to modulate chaperone activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones*
Pratt, W. B., & Toft, D. O. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.3.0303 · Cited by 1,791
Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)80314-1 · Cited by 1,265
The biology of heat shock proteins and molecular chaperones
Buchner, J. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90065-5 · Cited by 1,205
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004
Grenert, J. P., Sullivan, W. P., Fadden, P., Haystead, T. A. J., Clark, J., Mimnaugh, E., Krutzsch, H., Ochel, H.-J., Schulte, T. W., Sausville, E., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.38.23843 · Cited by 569
Self-citationMammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4
Stepanova, L., Leng, X., Parker, S. B., & Harper, J. W. (1996) · Genes & Development · doi:10.1101/gad.10.12.1491 · Cited by 483
Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones
Prodromou, C. (1999) · The EMBO Journal · doi:10.1093/emboj/18.3.754 · Cited by 425
Novobiocin and Related Coumarins and Depletion of Heat Shock Protein 90-Dependent Signaling Proteins
Marcu, M. G., Schulte, T. W., & Neckers, L. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.242 · Cited by 405
Self-citationMutant conformation of p53 translated in vitro or in vivo requires functional HSP90.
Blagosklonny, M. V., Toretsky, J., Bohen, S., & Neckers, L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8379 · Cited by 314
Self-citation
Cited by
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Schopf, F. H., Biebl, M. M., & Buchner, J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.20 · Cited by 1,540
Pratt, W. B., & Toft, D. O. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800201 · Cited by 1,483
Coumarin-Based Small-Molecule Fluorescent Chemosensors
Cao, D., Liu, Z., Verwilst, P., Koo, S., Jangjili, P., Kim, J. S., & Lin, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00145 · Cited by 1,306
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Neckers, L., & Workman, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1000 · Cited by 891
Self-citationHeat-shock protein 90, a chaperone for folding and regulation
Picard, D. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/pl00012491 · Cited by 796
Heat Shock Proteins and Cancer
Wu, J., Liu, T., Rios, Z., Mei, Q., Lin, X., & Cao, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.11.009 · Cited by 696
Hsp90 inhibitors as novel cancer chemotherapeutic agents
Neckers, L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02316-x · Cited by 677
Self-citationHsp90 isoforms: functions, expression and clinical importance
Subbarao Sreedhar, A., Kalmár, É., Csermely, P., & Shen, Y.-F. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00229-7 · Cited by 620
Hsp70 and Hsp90—a relay team for protein folding
Wegele, H., Müller, L., & Buchner, J. (2004) · Reviews of Physiology, Biochemistry and Pharmacology · doi:10.1007/s10254-003-0021-1 · Cited by 605
HSP90 as a new therapeutic target for cancer therapy: the story unfolds
Maloney, A., & Workman, P. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.1.3 · Cited by 531
WORKMAN, P., BURROWS, F., NECKERS, L., & ROSEN, N. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1391.012 · Cited by 521
Self-citationThe Hsp90 molecular chaperone: an open and shut case for treatment
Pearl, L. H., Prodromou, C., & Workman, P. (2008) · Biochemical Journal · doi:10.1042/bj20071640 · Cited by 447
Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy
Sreedhar, A. S., & Csermely, P. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.004 · Cited by 418
Marzec, M., Eletto, D., & Argon, Y. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.10.013 · Cited by 390
Heat shock proteins as emerging therapeutic targets
Sõti, C., Nagy, E., Giricz, Z., Vígh, L., Csermely, P., & Ferdinandy, P. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706396 · Cited by 380
Targeting multiple signal transduction pathways through inhibition of Hsp90
Zhang, H., & Burrows, F. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0549-9 · Cited by 377
Characterization of quercetin binding site on DNA gyrase
Plaper, A., Golob, M., Hafner, I., Oblak, M., Šolmajer, T., & Jerala, R. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01006-4 · Cited by 369
Zhou, J., Gelot, C., Pantelidou, C., Li, A., Yücel, H., Davis, R. E., Färkkilä, A., Kochupurakkal, B., Syed, A., Shapiro, G. I., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00203-x · Cited by 352
Regulation and function of the human HSP90AA1 gene
Zuehlke, A. D., Beebe, K., Neckers, L., & Prince, T. (2015) · Gene · doi:10.1016/j.gene.2015.06.018 · Cited by 347
Self-citationRational design of shepherdin, a novel anticancer agent
Plescia, J., Salz, W., Xia, F., Pennati, M., Zaffaroni, N., Daidone, M. G., Meli, M., Dohi, T., Fortugno, P., Nefedova, Y., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.035 · Cited by 341
The Hsp90 chaperone complex as a novel target for cancer therapy
Goetz, M. P., Toft, D. O., Ames, M. M., & Erlichman, C. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg316 · Cited by 334
Martínez-Ruiz, A., Villanueva, L., de Orduña, C. G., López-Ferrer, D., Higueras, M. Á., Tarín, C., Rodríguez-Crespo, I., Vázquez, J., & Lamas, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407294102 · Cited by 330
Inhibitors of the heat shock response: Biology and pharmacology
Powers, M. V., & Workman, P. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.05.040 · Cited by 320
Novobiocin and Additional Inhibitors of the Hsp90 C-Terminal Nucleotide- binding Pocket
Donnelly, A., & Blagg, B. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708786242895 · Cited by 313
Inhibitors of the HSP90 Molecular Chaperone: Current Status
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)95009-x · Cited by 310
Conformational dynamics of the molecular chaperone Hsp90
Krukenberg, K. A., Street, T. O., Lavery, L. A., & Agard, D. A. (2011) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583510000314 · Cited by 308
Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases
Neef, D. W., Jaeger, A. M., & Thiele, D. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3453 · Cited by 307
Structure, Function, and Regulation of the Hsp90 Machinery
Biebl, M. M., & Buchner, J. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a034017 · Cited by 304
Altered Hsp90 function in cancer: A unique therapeutic opportunity
Bagatell, R., & Whitesell, L. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1021.3.8 · Cited by 302
Walsh, D. P., & Chang, Y.-T. (2006) · Chemical Reviews · doi:10.1021/cr0404141 · Cited by 296
Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms
Wright, L., Barril, X., Dymock, B., Sheridan, L., Surgenor, A., Beswick, M., Drysdale, M., Collier, A., Massey, A., Davies, N., et al. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.03.033 · Cited by 268
Regulators of endothelial and epithelial barrier integrity and function in acute lung injury
Lucas, R., Verin, A. D., Black, S. M., & Catravas, J. D. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.01.014 · Cited by 263
Endothelial nitric oxide (NO) and its pathophysiologic regulation
Chatterjee, A., & Catravas, J. D. (2008) · Vascular Pharmacology · doi:10.1016/j.vph.2008.06.008 · Cited by 236
“…the chaperone’s ADP-bound “open” conformation, and this results in the recruitment of other hsp90-interacting proteins such as E3 ubiquitin ligases (e.g. CHIP) which interact with hsp90 and promote ubiquitylation and subsequent proteasomal degradation of client proteins (Marcu et al., 2000).”
BackgroundCHIP: a quality-control E3 ligase collaborating with molecular chaperones
Murata, S., Chiba, T., & Tanaka, K. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00394-1 · Cited by 218
Lu, S.-H., Wu, J. W., Liu, H.-L., Zhao, J.-H., Liu, K.-T., Chuang, C.-K., Lin, H.-Y., Tsai, W.-B., & Ho, Y. (2011) · Journal of Biomedical Science · doi:10.1186/1423-0127-18-8 · Cited by 204
Old and New Approaches to Target the Hsp90 Chaperone
Sanchez, J., Carter, T. R., Cohen, M. S., & Blagg, B. S. J. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009619666191202101330 · Cited by 183
The Influence of ATP and p23 on the Conformation of hsp90
Sullivan, W. P., Owen, B. A. L., & Toft, D. O. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207754200 · Cited by 111
Verkhivker, G. M., Agajanian, S., Hu, G., & Tao, P. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00136 · Cited by 76
Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances
Yu, J., Zhang, C., & Song, C. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114516 · Cited by 51
Metadata
- Authors
- Marcu, M. G., Chadli, A., Bouhouche, I., Catelli, M., & Neckers, L. M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-11
- Volume
- 275
- Issue
- 47
- Pages
- 37181-37186
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2054290614
- Cited by
- 502
- References
- 36
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.